deep cyclic inhibitors

Oncology

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

News

After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.